<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.36485/1561-6274-2024-28-2-9-22</article-id><article-id custom-type="edn" pub-id-type="custom">TCEXTL</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-2311</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПЕРЕДОВАЯ СТАТЬЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LEADING ARTICLE</subject></subj-group></article-categories><title-group><article-title>Устранение пробелов в лечении почек: воплощение того, что мы знаем, в то, что мы делаем</article-title><trans-title-group xml:lang="en"><trans-title>Mind the gap in kidney care: translating what we know into what we do</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ликс</surname><given-names>Валери А.</given-names></name><name name-style="western" xml:lang="en"><surname>Luyckx</surname><given-names>Valerie A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хиршенграбен 84, Цюрих 8001, Швейцария</p></bio><bio xml:lang="en"><p>Hirschen-graben 84, Zurich 8001</p></bio><email xlink:type="simple">valerie.luyckx@uzh.ch</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Таттл</surname><given-names>Кэтрин Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Tuttle</surname><given-names>Katherine R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>105 W 8th Avenue, Suite 250 E, Спокан, Вашингтон 99204, США</p></bio><bio xml:lang="en"><p>105 W 8th Avenue, Suite 250 E, Spokane, Washington 99204</p></bio><email xlink:type="simple">katherine.tuttle@providence.org</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Абделлатиф</surname><given-names>Дина</given-names></name><name name-style="western" xml:lang="en"><surname>Abdellatif</surname><given-names>Dina</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Каир</p></bio><bio xml:lang="en"><p>Cairo</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Корреа-Роттер</surname><given-names>Рикардо</given-names></name><name name-style="western" xml:lang="en"><surname>Correa-Rotter</surname><given-names>Ricardo</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Мехико</p></bio><bio xml:lang="en"><p>Mexico City</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фунг</surname><given-names>Уинстан В.С.</given-names></name><name name-style="western" xml:lang="en"><surname>Fung</surname><given-names>Winston W.S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>девятый этаж, Lui Che Woo Clinical Science Bldg, 32 Ngan Shing St, Шатин</p></bio><bio xml:lang="en"><p>Ninth Floor, Lui Che Woo Clinical Science Bldg, 32 Ngan Shing St, Shatin</p></bio><email xlink:type="simple">fws898@ha.org.hk</email><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Харис</surname><given-names>Агнес</given-names></name><name name-style="western" xml:lang="en"><surname>Haris</surname><given-names>Agnès</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Будапешт</p></bio><bio xml:lang="en"><p>Budapest</p></bio><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сяо</surname><given-names>Ли-Ли</given-names></name><name name-style="western" xml:lang="en"><surname>Hsiao</surname><given-names>Li-Li</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Бостон, Массачусетс</p></bio><bio xml:lang="en"><p>Boston, Massachusetts</p></bio><xref ref-type="aff" rid="aff-7"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Халиф</surname><given-names>Макрам</given-names></name><name name-style="western" xml:lang="en"><surname>Khalife</surname><given-names>Makram</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-8"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кумарасвами</surname><given-names>Лата А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kumaraswami</surname><given-names>Latha A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Ченнаи</p></bio><bio xml:lang="en"><p>Chennai</p></bio><xref ref-type="aff" rid="aff-9"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лауд</surname><given-names>Фиона</given-names></name><name name-style="western" xml:lang="en"><surname>Loud</surname><given-names>Fiona</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-8"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рагхаван</surname><given-names>Васундхара</given-names></name><name name-style="western" xml:lang="en"><surname>Raghavan</surname><given-names>Vasundhara</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-8"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Роумелиотис</surname><given-names>Стефанос</given-names></name><name name-style="western" xml:lang="en"><surname>Roumeliotis</surname><given-names>Stefanos</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Салоники</p></bio><xref ref-type="aff" rid="aff-10"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сьерра</surname><given-names>Марианелла</given-names></name><name name-style="western" xml:lang="en"><surname>Sierra</surname><given-names>Marianella</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-8"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Уласи</surname><given-names>Ифеома</given-names></name><name name-style="western" xml:lang="en"><surname>Ulasi</surname><given-names>Ifeoma</given-names></name></name-alternatives><bio xml:lang="ru"><p>Итуку-Озалла, г. Энугу</p></bio><bio xml:lang="en"><p>Ituku-Ozalla</p></bio><xref ref-type="aff" rid="aff-11"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вонг</surname><given-names>Билл</given-names></name><name name-style="western" xml:lang="en"><surname>Wang</surname><given-names>Bill</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-8"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Луи</surname><given-names>Сиу-Фаи</given-names></name><name name-style="western" xml:lang="en"><surname>Lui</surname><given-names>Siu-Fai</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гонконг</p></bio><bio xml:lang="en"><p>Hong Kong</p></bio><xref ref-type="aff" rid="aff-12"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лиакопулос</surname><given-names>Вассилиос</given-names></name><name name-style="western" xml:lang="en"><surname>Liakopoulos</surname><given-names>Vassilios</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Салоники</p></bio><bio xml:lang="en"><p>Thessaloniki</p></bio><xref ref-type="aff" rid="aff-10"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Балдуччи</surname><given-names>Алессандро</given-names></name><name name-style="western" xml:lang="en"><surname>Balducci</surname><given-names>Alessandro</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Рим</p></bio><bio xml:lang="en"><p>Rome</p></bio><xref ref-type="aff" rid="aff-13"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>от имени Объединенного организационного комитета Всемирного  Дня Почки.</surname><given-names>.</given-names></name><name name-style="western" xml:lang="en"><surname>For the World Kidney Day Joint Steering Committee.</surname><given-names>.</given-names></name></name-alternatives></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Отдел общественного и глобального здоровья, Институт эпидемиологии, биостатистики и профилактики, Цюрихский университет; почечное отделение, медицинский отдел, Женская больница Бригама, Медицинская школа Гарварда; Отдел педиатрии и детского здоровья, Кейптаунский университет</institution><country>Швейцария</country></aff><aff xml:lang="en"><institution>Department of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich; Renal Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School; Department of Paediatrics and Child Health, University of Cape Town</institution><country>Switzerland</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Медицинский исследовательский центр Провиденс, Северо-западная некоммерческая организация здравоохранения; Нефрологическое отделение, медицинский факультет, Университет Вашингтона</institution><country>Соединённые Штаты Америки</country></aff><aff xml:lang="en"><institution>Providence Medical Research Center, Providence Inland Northwest Health; Nephrology Division, Department of Medicine, University of Washington</institution><country>United States</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Отделение нефрологии, Каирская университетская больница</institution><country>Египет</country></aff><aff xml:lang="en"><institution>Department of Nephrology, Cairo University Hospital</institution><country>Egypt</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Отделение нефрологии и минерального метаболизма, Национальный институт медицинских наук и питания Сальвадора Зубирана</institution><country>Мексика</country></aff><aff xml:lang="en"><institution>Department of Nephrology and Mineral Metabolism, National Medical Science and Nutrition Institute Salvador Zubiran</institution><country>Mexico</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>Отдел медицины и терапии, больница принца Уэльского, Китайский университет Гонконга</institution><country>Гонконг</country></aff><aff xml:lang="en"><institution>Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong</institution><country>Hong Kong</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>Нефрологическое отделение, больница Петефи</institution><country>Венгрия</country></aff><aff xml:lang="en"><institution>Nephrology Department, Péterfy Hospital</institution><country>Hungary</country></aff></aff-alternatives><aff-alternatives id="aff-7"><aff xml:lang="ru"><institution>почечное отделение, медицинский отдел, Женская больница Бригама, Медицинская школа Гарварда</institution><country>Соединённые Штаты Америки</country></aff><aff xml:lang="en"><institution>Renal Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School</institution><country>United States</country></aff></aff-alternatives><aff-alternatives id="aff-8"><aff xml:lang="ru"><institution>Консультативная группа по связям с пациентами ISN</institution><country>Россия</country></aff><aff xml:lang="en"><institution>ISN Patient Liaison Advisory Group</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-9"><aff xml:lang="ru"><institution>Исследовательский Почечный Фонд Тамилнада (TANKER)</institution><country>Индия</country></aff><aff xml:lang="en"><institution>Tamilnad Kidney Research (TANKER) Foundation</institution><country>India</country></aff></aff-alternatives><aff-alternatives id="aff-10"><aff xml:lang="ru"><institution>2-е отделение нефрологии, Медицинская школа при университетской больнице Эллинской американской образовательной ассоциации, Университет Аристотеля в Салониках</institution><country>Греция</country></aff><aff xml:lang="en"><institution>2nd Department of Nephrology, AHEPA University Hospital Medical School, Aristotle University of Thessaloniki</institution><country>Greece</country></aff></aff-alternatives><aff-alternatives id="aff-11"><aff xml:lang="ru"><institution>Медицинский факультет, Медицинский колледж Нигерийского университета</institution><country>Нигерия</country></aff><aff xml:lang="en"><institution>Department of Medicine, College of Medicine, University of Nigeria</institution><country>Nigeria</country></aff></aff-alternatives><aff-alternatives id="aff-12"><aff xml:lang="ru"><institution>Отдел системы здравоохранения, политики и управления Гонконгского жокей-клуба, Китайский университет Гонконга</institution><country>Китай</country></aff><aff xml:lang="en"><institution>Division of Health System, Policy and Management, Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong</institution><country>China</country></aff></aff-alternatives><aff-alternatives id="aff-13"><aff xml:lang="ru"><institution>Итальянский почечный фонд</institution><country>Италия</country></aff><aff xml:lang="en"><institution>Italian Kidney Foundation</institution><country>Italy</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>12</day><month>07</month><year>2024</year></pub-date><volume>28</volume><issue>2</issue><fpage>9</fpage><lpage>22</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ликс В.А., Таттл К.Р., Абделлатиф Д., Корреа-Роттер Р., Фунг У.В., Харис А., Сяо Л., Халиф М., Кумарасвами Л.А., Лауд Ф., Рагхаван В., Роумелиотис С., Сьерра М., Уласи И., Вонг Б., Луи С., Лиакопулос В., Балдуччи А., от имени Объединенного организационного комитета Всемирного  Дня Почки. .., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Ликс В.А., Таттл К.Р., Абделлатиф Д., Корреа-Роттер Р., Фунг У.В., Харис А., Сяо Л., Халиф М., Кумарасвами Л.А., Лауд Ф., Рагхаван В., Роумелиотис С., Сьерра М., Уласи И., Вонг Б., Луи С., Лиакопулос В., Балдуччи А., от имени Объединенного организационного комитета Всемирного  Дня Почки. ..</copyright-holder><copyright-holder xml:lang="en">Luyckx V.A., Tuttle K.R., Abdellatif D., Correa-Rotter R., Fung W.W., Haris A., Hsiao L., Khalife M., Kumaraswami L.A., Loud F., Raghavan V., Roumeliotis S., Sierra M., Ulasi I., Wang B., Lui S., Liakopoulos V., Balducci A., for the World Kidney Day Joint Steering Committee. ..</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/2311">https://journal.nephrolog.ru/jour/article/view/2311</self-uri><abstract><p>Исторически сложилось так, что на процесс перехода новых методов лечения из области клинических доказательств в повседневную практику уходит в среднем 17 лет. Учитывая существование в настоящее время высокоэффективных методов лечения, позволяющих предотвратить или отсрочить развитие и прогрессирование заболеваний почек, это слишком долгий срок. Настало время сократить разрыв между тем, что мы знаем, и тем, что мы делаем. Существуют четкие рекомендации по профилактике и управлению распространенными факторами риска развития заболеваний почек, такими как гипертония и диабет, но во всем мире лишь у части людей с этими заболеваниями установлен диагноз, а еще меньше – получают целевое лечение. Аналогичным образом подавляющее большинство людей, живущих с заболеваниями почек, не знают о своем состоянии, поскольку на ранних стадиях оно часто протекает бессимптомно. И даже среди пациентов, которым диагноз был установлен, многие не получают надлежащего лечения по поводу болезни почек. Учитывая серьезные последствия прогрессирования болезни почек – утрату функции почек или смерть, – крайне важно начать лечение на ранних стадиях и должным образом. Возможности ранней диагностики и лечения заболеваний почек должны быть максимально расширены, начинаясь с уровня первичной медицинской помощи. Существуют множество систематических препятствий, начиная с самих пациентов и врачей и заканчивая уровнем системы здравоохранения и общественными факторами. Для сохранения и улучшения здоровья почек всех и каждого необходимо признать существование каждого из этих барьеров, чтобы разработать устойчивые решения и внедрять их без дальнейших задержек.</p></abstract><trans-abstract xml:lang="en"><p>Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая болезнь почек</kwd><kwd>равенство</kwd><kwd>лечение заболеваний почек</kwd><kwd>общественное здоровье</kwd><kwd>Всемирный день почки</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic kidney disease</kwd><kwd>equity</kwd><kwd>kidney care</kwd><kwd>public health</kwd><kwd>World Kidney Day</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Авторы благодарят за вклад, внесенный в эту работу, членов Рабочей группы по защите интересов и Консультативной группы по связи с пациентами Международного общества нефрологов: Эллиота Тэннора, Марчелло Тонелли, Бориса Бикбова, Марию Карлоту Гонзалес, Вивекананда Джа и Вивиан Каличе-Сильва.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Jager KJ, Kovesdy С, Langham R et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 96 (2019):1048–1050</mixed-citation><mixed-citation xml:lang="en">Jager KJ, Kovesdy С, Langham R et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 96 (2019):1048–1050</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Institute for Health Metrics and Evaluation (IHME). GBD compare data visualization. Accessed November 18, 2023. http://vizhub.healthdata.org/gbd-compare</mixed-citation><mixed-citation xml:lang="en">Institute for Health Metrics and Evaluation (IHME). GBD compare data visualization. Accessed November 18, 2023. http://vizhub.healthdata.org/gbd-compare</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ 96 (2018): 414–422D</mixed-citation><mixed-citation xml:lang="en">Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ 96 (2018): 414–422D</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">International Society of Nephrology. ISN Global Kidney Health Atlas, 3rd ed. Accessed November 18, 2023. https://www.theisn.org/initiatives/global-kidney-health-atlas/</mixed-citation><mixed-citation xml:lang="en">International Society of Nephrology. ISN Global Kidney Health Atlas, 3rd ed. Accessed November 18, 2023. https://www.theisn.org/initiatives/global-kidney-health-atlas/</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395 (2020) 709–733</mixed-citation><mixed-citation xml:lang="en">GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395 (2020) 709–733</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Vanholder R, Annemans L, Brown E et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol 13 (2017) 393–409</mixed-citation><mixed-citation xml:lang="en">Vanholder R, Annemans L, Brown E et al. Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol 13 (2017) 393–409</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Nguyen-Thi HY, Le-Phuoc TN, Tri Phat N et al. The economic burden of chronic kidney disease in Vietnam. Health Serv Insights 14, 2021</mixed-citation><mixed-citation xml:lang="en">Nguyen-Thi HY, Le-Phuoc TN, Tri Phat N et al. The economic burden of chronic kidney disease in Vietnam. Health Serv Insights 14, 2021</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">US Renal Data System. Healthcare expenditures for persons with CKD. https://usrds-adr.niddk.nih.gov/2023/chronickidney-disease/6-healthcare-expenditures-for-persons-with-ckd</mixed-citation><mixed-citation xml:lang="en">US Renal Data System. Healthcare expenditures for persons with CKD. https://usrds-adr.niddk.nih.gov/2023/chronickidney-disease/6-healthcare-expenditures-for-persons-with-ckd</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kidney Health Australia. Transforming Australia’s kidney health: a call to action for early detection and treatment of chronic kidney disease. Accessed January 16, 2024. https://kidney.org.au/uploads/resources/Changing-the-CKD-landscape-Economicbenefits-of-early-detection-and-treatment.pdf</mixed-citation><mixed-citation xml:lang="en">Kidney Health Australia. Transforming Australia’s kidney health: a call to action for early detection and treatment of chronic kidney disease. Accessed January 16, 2024. https://kidney.org.au/uploads/resources/Changing-the-CKD-landscape-Economicbenefits-of-early-detection-and-treatment.pdf</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ke C, Liang J, Liu M et al. Burden of chronic kidney disease and its risk-attributable burden in 137 low-and middle-income countries, 1990-2019: results from the global burden of disease study 2019. BMC Nephrol 23 (2022):17</mixed-citation><mixed-citation xml:lang="en">Ke C, Liang J, Liu M et al. Burden of chronic kidney disease and its risk-attributable burden in 137 low-and middle-income countries, 1990-2019: results from the global burden of disease study 2019. BMC Nephrol 23 (2022):17</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Gregg EW , Buckley J, Ali MK et al. Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact. Lancet 401 (2023): 1302–1312</mixed-citation><mixed-citation xml:lang="en">Gregg EW , Buckley J, Ali MK et al. Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact. Lancet 401 (2023): 1302–1312</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Geldsetzer P, Manne-Goehler J, Marcus ME et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults. Lancet 394 (2019): 652–662</mixed-citation><mixed-citation xml:lang="en">Geldsetzer P, Manne-Goehler J, Marcus ME et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults. Lancet 394 (2019): 652–662</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chu L, Bhogal SK, Lin P et al. AWAREness of Diagnosis and Treatment of Chronic Kidney Disease in Adults With Type 2 Diabetes (AWARE-CKD in T2D). Can J Diabetes 46 (2022): 464–472</mixed-citation><mixed-citation xml:lang="en">Chu L, Bhogal SK, Lin P et al. AWAREness of Diagnosis and Treatment of Chronic Kidney Disease in Adults With Type 2 Diabetes (AWARE-CKD in T2D). Can J Diabetes 46 (2022): 464–472</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Levin A, Tonelli M, Bonventre J et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 390 (2017):1888–1917</mixed-citation><mixed-citation xml:lang="en">Levin A, Tonelli M, Bonventre J et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 390 (2017):1888–1917</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Stengel B, Muenz D, Tu C et al. Adherence to the Kidney Disease: Improving Global Outcomes CKD guideline in nephrology practice across countries. Kidney Int Rep 6 (2021): 437–448</mixed-citation><mixed-citation xml:lang="en">Stengel B, Muenz D, Tu C et al. Adherence to the Kidney Disease: Improving Global Outcomes CKD guideline in nephrology practice across countries. Kidney Int Rep 6 (2021): 437–448</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Chu CD, Chen MH, McCulloch CE et al. Patient awareness of CKD: a systematic review and meta-analysis of patient-oriented questions and study setting. Kidney Med 3 (2021): 576–585.e1</mixed-citation><mixed-citation xml:lang="en">Chu CD, Chen MH, McCulloch CE et al. Patient awareness of CKD: a systematic review and meta-analysis of patient-oriented questions and study setting. Kidney Med 3 (2021): 576–585.e1</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ene-Iordache B, Perico N, Bikbov B et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISNKDDC): a cross-sectional study. Lancet Global Health 4 (2016): e307–e319</mixed-citation><mixed-citation xml:lang="en">Ene-Iordache B, Perico N, Bikbov B et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISNKDDC): a cross-sectional study. Lancet Global Health 4 (2016): e307–e319</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Gummidi B, John O, Ghosh A et al. A systematic study of the prevalence and risk factors of CKD in Uddanam, India. Kidney Int Rep 5 (2020): 2246–2255</mixed-citation><mixed-citation xml:lang="en">Gummidi B, John O, Ghosh A et al. A systematic study of the prevalence and risk factors of CKD in Uddanam, India. Kidney Int Rep 5 (2020): 2246–2255</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 102 (5S) (2022): S1–S127</mixed-citation><mixed-citation xml:lang="en">Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 102 (5S) (2022): S1–S127</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Nicho las SB, Daratha KB, Alicic RZ et al. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019–2020. Diabetes Obes Metab 25 (2023): 2970–2979</mixed-citation><mixed-citation xml:lang="en">Nicho las SB, Daratha KB, Alicic RZ et al. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019–2020. Diabetes Obes Metab 25 (2023): 2970–2979</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Grams ME, Yang W, Rebholz CM et al. Risks of adverse events in advanced CKD: the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis 70 (2017): 337–346</mixed-citation><mixed-citation xml:lang="en">Grams ME, Yang W, Rebholz CM et al. Risks of adverse events in advanced CKD: the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis 70 (2017): 337–346</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. https://doi.org/10.1016/j.kint.2023.10.018</mixed-citation><mixed-citation xml:lang="en">Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. https://doi.org/10.1016/j.kint.2023.10.018</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99 (3S) (2021): S1–S87</mixed-citation><mixed-citation xml:lang="en">Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99 (3S) (2021): S1–S87</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Tuttle KR, Alicic R Z, Duru OK et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Netw Open 2, 2019</mixed-citation><mixed-citation xml:lang="en">Tuttle KR, Alicic R Z, Duru OK et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Netw Open 2, 2019</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Ismail WW, Witry MJ, Urmie JM. The association between cost sharing, prior authorization, and specialty drug utilization: a systematic review. J Manag Care Spec Pharm 29 (2023): 449–463</mixed-citation><mixed-citation xml:lang="en">Ismail WW, Witry MJ, Urmie JM. The association between cost sharing, prior authorization, and specialty drug utilization: a systematic review. J Manag Care Spec Pharm 29 (2023): 449–463</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Heerspink HJL, Vart P, Jongs N et al. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes Obes Metab 25 (2023): 3327–3336</mixed-citation><mixed-citation xml:lang="en">Heerspink HJL, Vart P, Jongs N et al. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes Obes Metab 25 (2023): 3327–3336</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Nuffield Department of Population Health Renal Studies Group. SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400 (2022):1788–1801</mixed-citation><mixed-citation xml:lang="en">Nuffield Department of Population Health Renal Studies Group. SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400 (2022):1788–1801</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Fernández-Fernandez B, Sarafidis P, Soler MJ et al. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J 16 (2023):1187–1198</mixed-citation><mixed-citation xml:lang="en">Fernández-Fernandez B, Sarafidis P, Soler MJ et al. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J 16 (2023):1187–1198</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">McEwan P, Boyce R, Sanchez JJG et al. Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. Nephrol Dial Transplant 38 (2023): 1260–1270</mixed-citation><mixed-citation xml:lang="en">McEwan P, Boyce R, Sanchez JJG et al. Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. Nephrol Dial Transplant 38 (2023): 1260–1270</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Vanholder R, Annemans L, Braks M et al. Inequities in kidney health and kidney care. Nat Rev Nephrol 19 (2023): 694–708</mixed-citation><mixed-citation xml:lang="en">Vanholder R, Annemans L, Braks M et al. Inequities in kidney health and kidney care. Nat Rev Nephrol 19 (2023): 694–708</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Agarwal R, Filippatos G, Pitt B et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43 (2022): 474–484</mixed-citation><mixed-citation xml:lang="en">Agarwal R, Filippatos G, Pitt B et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43 (2022): 474–484</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Tuttle KR, Bosch-Traberg H, Cherney DZI et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int 103 (2023): 772–781</mixed-citation><mixed-citation xml:lang="en">Tuttle KR, Bosch-Traberg H, Cherney DZI et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int 103 (2023): 772–781</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Rubin R. It takes an average of 17 years for evidence to change practice-the burgeoning field of implementation science seeks to speed things up. JAMA 329 (2023): 1333–1336</mixed-citation><mixed-citation xml:lang="en">Rubin R. It takes an average of 17 years for evidence to change practice-the burgeoning field of implementation science seeks to speed things up. JAMA 329 (2023): 1333–1336</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organisation. Mid-point evaluation of the implementation of the WHO global action plan for the prevention and control of noncommunicable diseases 2013–2020 (NCDGAP). Accessed November 18, 2023. https://cdn.who.int/media/docs/default-source/documents/about-us/evaluation/ncd-gapfinal-report.pdf?sfvrsn=55b22b89_5&amp;download=true</mixed-citation><mixed-citation xml:lang="en">World Health Organisation. Mid-point evaluation of the implementation of the WHO global action plan for the prevention and control of noncommunicable diseases 2013–2020 (NCDGAP). Accessed November 18, 2023. https://cdn.who.int/media/docs/default-source/documents/about-us/evaluation/ncd-gapfinal-report.pdf?sfvrsn=55b22b89_5&amp;download=true</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Kruk ME, Gage AD, Joseph NT et al. Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries. Lancet 392 (2018): 2203–2212</mixed-citation><mixed-citation xml:lang="en">Kruk ME, Gage AD, Joseph NT et al. Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries. Lancet 392 (2018): 2203–2212</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Kingori P, Peeters Grietens K, Abimbola S. et al. Uncertainties about the quality of medical products globally: lessons from multidisciplinary research. BMJ Glob Health 6, 2023</mixed-citation><mixed-citation xml:lang="en">Kingori P, Peeters Grietens K, Abimbola S. et al. Uncertainties about the quality of medical products globally: lessons from multidisciplinary research. BMJ Glob Health 6, 2023</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Pan American Health Organization Quality control of medicines. Accessed November 18, 2023. https://www.paho.org/en/topics/quality-control-medicines</mixed-citation><mixed-citation xml:lang="en">Pan American Health Organization Quality control of medicines. Accessed November 18, 2023. https://www.paho.org/en/topics/quality-control-medicines</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Tuttle KR, Wong L, St Peter W et al. Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. Clin J Am Soc Nephrol 17 (2022): 1092–1103</mixed-citation><mixed-citation xml:lang="en">Tuttle KR, Wong L, St Peter W et al. Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. Clin J Am Soc Nephrol 17 (2022): 1092–1103</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Kalyesubula R, Conroy AL, Calice-Silva V et al. Screening for kidney disease in low- and middle-income countries. Semin Nephrol 42, 2022</mixed-citation><mixed-citation xml:lang="en">Kalyesubula R, Conroy AL, Calice-Silva V et al. Screening for kidney disease in low- and middle-income countries. Semin Nephrol 42, 2022</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Francis A, Abdul Hafidz MI, Ekrikpo UE et al. Barriers to accessing essential medicines for kidney disease in low- and lower middle-income countries. Kidney Int 102 (2022): 969–973</mixed-citation><mixed-citation xml:lang="en">Francis A, Abdul Hafidz MI, Ekrikpo UE et al. Barriers to accessing essential medicines for kidney disease in low- and lower middle-income countries. Kidney Int 102 (2022): 969–973</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Rangaswami J, Tuttle K, Vaduganathan M . Cardio-renal-metabolic care models: toward achieving effective interdisciplinary care. Circ Cardiovasc Qual Outcomes 13, 2020</mixed-citation><mixed-citation xml:lang="en">Rangaswami J, Tuttle K, Vaduganathan M . Cardio-renal-metabolic care models: toward achieving effective interdisciplinary care. Circ Cardiovasc Qual Outcomes 13, 2020</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Neumiller JJ, Alicic RZ, Tuttle KR. Overcoming barriers to implementing new therapies for diabetic kidney disease: lessons learned. Adv Chronic Kidney Dis 28 (2021): 318–327</mixed-citation><mixed-citation xml:lang="en">Neumiller JJ, Alicic RZ, Tuttle KR. Overcoming barriers to implementing new therapies for diabetic kidney disease: lessons learned. Adv Chronic Kidney Dis 28 (2021): 318–327</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Mishra SR, Neupane D, Preen D et al. Mitigation of non-communicable diseases in developing countries with community health workers. Global Health 11 (2015): 43</mixed-citation><mixed-citation xml:lang="en">Mishra SR, Neupane D, Preen D et al. Mitigation of non-communicable diseases in developing countries with community health workers. Global Health 11 (2015): 43</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Joshi R, John O, Jha V. The potential impact of public health interventions in preventing kidney disease. Semin Nephrol 37 (2017): 234–244</mixed-citation><mixed-citation xml:lang="en">Joshi R, John O, Jha V. The potential impact of public health interventions in preventing kidney disease. Semin Nephrol 37 (2017): 234–244</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Patel A, Praveen D, Maharani A et al. Association of multi-faceted mobile technology-enabled primary care intervention with cardiovascular disease risk management in rural Indonesia. JAMA Cardiol 4 (2019): 978–986</mixed-citation><mixed-citation xml:lang="en">Patel A, Praveen D, Maharani A et al. Association of multi-faceted mobile technology-enabled primary care intervention with cardiovascular disease risk management in rural Indonesia. JAMA Cardiol 4 (2019): 978–986</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Ardavani A, Curtis F, Khunti K et al. The effect of pharmacist-led interventions on the management and outcomes in chronic kidney disease (CKD): a systematic review and meta-analysis protocol. Health Sci Rep 6, 2023</mixed-citation><mixed-citation xml:lang="en">Ardavani A, Curtis F, Khunti K et al. The effect of pharmacist-led interventions on the management and outcomes in chronic kidney disease (CKD): a systematic review and meta-analysis protocol. Health Sci Rep 6, 2023</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Sherrod CF, Farr SL, Sauer AJ. Overcoming treatment inertia for patients with heart failure: how do we build systems that move us from rest to motion? Eur Heart J 44 (2023): 1970–1972</mixed-citation><mixed-citation xml:lang="en">Sherrod CF, Farr SL, Sauer AJ. Overcoming treatment inertia for patients with heart failure: how do we build systems that move us from rest to motion? Eur Heart J 44 (2023): 1970–1972</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Ramakrishnan C, Tan NC, Yoon S et al. Healthcare professionals' perspectives on facilitators of and barriers to CKD management in primary care: a qualitative study in Singapore clinics. BMC Health Services Res 22 (2022): 560</mixed-citation><mixed-citation xml:lang="en">Ramakrishnan C, Tan NC, Yoon S et al. Healthcare professionals' perspectives on facilitators of and barriers to CKD management in primary care: a qualitative study in Singapore clinics. BMC Health Services Res 22 (2022): 560</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Porter J, Boyd C, Skandari MR et al. Revisiting the time needed to provide adult primary care. J Gen Intern Med 38 (2023): 147–155</mixed-citation><mixed-citation xml:lang="en">Porter J, Boyd C, Skandari MR et al. Revisiting the time needed to provide adult primary care. J Gen Intern Med 38 (2023): 147–155</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Peralta CA, Livaudais-Toman J, Stebbins M et al. Electronic decision support for management of CKD in primary care: a pragmatic randomized trial. Am J Kidney Dis 76 (2020): 636–644</mixed-citation><mixed-citation xml:lang="en">Peralta CA, Livaudais-Toman J, Stebbins M et al. Electronic decision support for management of CKD in primary care: a pragmatic randomized trial. Am J Kidney Dis 76 (2020): 636–644</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Rios P, Sola L, Ferreiro A et al. Adherence to multidisciplinary care in a prospective chronic kidney disease cohort is associated with better outcomes. PLoS One 17, 2022</mixed-citation><mixed-citation xml:lang="en">Rios P, Sola L, Ferreiro A et al. Adherence to multidisciplinary care in a prospective chronic kidney disease cohort is associated with better outcomes. PLoS One 17, 2022</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Stevenson JK, Campbell ZC, Webster AC et al. eHealth interventions for people with chronic kidney disease. Cochrane Database Syst Rev 8 (2019): Cd012379</mixed-citation><mixed-citation xml:lang="en">Stevenson JK, Campbell ZC, Webster AC et al. eHealth interventions for people with chronic kidney disease. Cochrane Database Syst Rev 8 (2019): Cd012379</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Tuot DS, Crowley ST, Katz LA et al. Usability testing of the kidney score platform to enhance communication about kidney disease in primary care settings: qualitative think-aloud study. JMIR Form Res 6, 2022</mixed-citation><mixed-citation xml:lang="en">Tuot DS, Crowley ST, Katz LA et al. Usability testing of the kidney score platform to enhance communication about kidney disease in primary care settings: qualitative think-aloud study. JMIR Form Res 6, 2022</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Verberne WR, Stiggelbout AM, Bos WJW et al. Asking the right questions: towards a person-centered conception of shared decision-making regarding treatment of advanced chronic kidney disease in older patients. BMC Med Ethics 23 (2022): 47</mixed-citation><mixed-citation xml:lang="en">Verberne WR, Stiggelbout AM, Bos WJW et al. Asking the right questions: towards a person-centered conception of shared decision-making regarding treatment of advanced chronic kidney disease in older patients. BMC Med Ethics 23 (2022): 47</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Taha A, Iman Y, Hingwala J et al. Patient navigators for CKD and kidney failure: a systematic review. Kidney Med 4, 2022</mixed-citation><mixed-citation xml:lang="en">Taha A, Iman Y, Hingwala J et al. Patient navigators for CKD and kidney failure: a systematic review. Kidney Med 4, 2022</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Essue BM, Laba M, Knaul F et al. Economic burden of chronic ill health and injuries for households in low- and middle-income countries. in: DT Jamison, H Gelband, S Hortonet al. (Eds.), Disease Control Priorities: Improving Health and Reducing Poverty. 3rd ed. The International Bank for Reconstruction and Development/The World Bank; 2017. https://doi.org/10.1596/978-14648-0527-1_ch6</mixed-citation><mixed-citation xml:lang="en">Essue BM, Laba M, Knaul F et al. Economic burden of chronic ill health and injuries for households in low- and middle-income countries. in: DT Jamison, H Gelband, S Hortonet al. (Eds.), Disease Control Priorities: Improving Health and Reducing Poverty. 3rd ed. The International Bank for Reconstruction and Development/The World Bank; 2017. https://doi.org/10.1596/978-14648-0527-1_ch6</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Khatib R, McKee M, Shannon H et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 387 (2016): 61–69</mixed-citation><mixed-citation xml:lang="en">Khatib R, McKee M, Shannon H et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 387 (2016): 61–69</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Kamath N, Iyengar AA. Chronic kidney disease (CKD): an observational study of etiology, severity and burden of comorbidities. Indian J Pediatr 84 (2017): 822–825</mixed-citation><mixed-citation xml:lang="en">Kamath N, Iyengar AA. Chronic kidney disease (CKD): an observational study of etiology, severity and burden of comorbidities. Indian J Pediatr 84 (2017): 822–825</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Cirillo L, Ravaglia F, Errichiello C et al. Expectations in children with glomerular diseases from SGLT2 inhibitors. Pediatr Nephrol 37 (2022): 2997–3008</mixed-citation><mixed-citation xml:lang="en">Cirillo L, Ravaglia F, Errichiello C et al. Expectations in children with glomerular diseases from SGLT2 inhibitors. Pediatr Nephrol 37 (2022): 2997–3008</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Donohue JF, Elborn JS, Lansberg P et al. Bridging the «know-do» gaps in five non-communicable diseases using a common framework driven by implementation science. J Healthc Leadersh 15 (2023):103–119</mixed-citation><mixed-citation xml:lang="en">Donohue JF, Elborn JS, Lansberg P et al. Bridging the «know-do» gaps in five non-communicable diseases using a common framework driven by implementation science. J Healthc Leadersh 15 (2023):103–119</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Population Health Research Institute. Polypills added to WHO essential medicines list. Accessed November 18, 2023. https://www.phri.ca/eml/</mixed-citation><mixed-citation xml:lang="en">Population Health Research Institute. Polypills added to WHO essential medicines list. Accessed November 18, 2023. https://www.phri.ca/eml/</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Sepanlou SG, Mann JFE, Joseph P et al. Fixed-dose combination therapy for prevention of cardiovascular diseases in CKD: an individual participant data meta-analysis. Clin J Am Soc Nephrol 18 (2023): 1408–1415</mixed-citation><mixed-citation xml:lang="en">Sepanlou SG, Mann JFE, Joseph P et al. Fixed-dose combination therapy for prevention of cardiovascular diseases in CKD: an individual participant data meta-analysis. Clin J Am Soc Nephrol 18 (2023): 1408–1415</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Dev V, Mittal A, Joshi V et al. Cost analysis of telemedicine use in paediatric nephrology-the LMIC perspective. Pediatr Nephrol 39 (2024): 193–201</mixed-citation><mixed-citation xml:lang="en">Dev V, Mittal A, Joshi V et al. Cost analysis of telemedicine use in paediatric nephrology-the LMIC perspective. Pediatr Nephrol 39 (2024): 193–201</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Musacchio N, Zilich R, Ponzani P et al. Transparent machine learning suggests a key driver in the decision to start insulin therapy in individuals with type 2 diabetes. J Diabetes 15 (2023): 224–236</mixed-citation><mixed-citation xml:lang="en">Musacchio N, Zilich R, Ponzani P et al. Transparent machine learning suggests a key driver in the decision to start insulin therapy in individuals with type 2 diabetes. J Diabetes 15 (2023): 224–236</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Zuniga C, Riquelme C, Muller H et al. Using telenephrology to improve access to nephrologist and global kidney management of CKD primary care patients. Kidney Int Rep 5 (2020): 920–923</mixed-citation><mixed-citation xml:lang="en">Zuniga C, Riquelme C, Muller H et al. Using telenephrology to improve access to nephrologist and global kidney management of CKD primary care patients. Kidney Int Rep 5 (2020): 920–923</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">van der Horst DEM, Hofstra N, van Uden-Kraan CF et al. Shared decision making in health care visits for CKD: patients' decisional role preferences and experiences. Am J Kidney Dis 82 (2023): 677–686</mixed-citation><mixed-citation xml:lang="en">van der Horst DEM, Hofstra N, van Uden-Kraan CF et al. Shared decision making in health care visits for CKD: patients' decisional role preferences and experiences. Am J Kidney Dis 82 (2023): 677–686</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Hole B, Scanlon M, Tomson C. Shared decision making: a personal view from two kidney doctors and a patient. Clin Kidney J 16 (2023): i12–i19</mixed-citation><mixed-citation xml:lang="en">Hole B, Scanlon M, Tomson C. Shared decision making: a personal view from two kidney doctors and a patient. Clin Kidney J 16 (2023): i12–i19</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
